Year: 2022

MIAMI, Dec. 13, 2022 (GLOBE NEWSWIRE) — International Money Express (NASDAQ: IMXI), (“Intermex” or the “Company”) a leading money remittance services company, today announced the Company will present at the 25th Anniversary ICR Conference in Orlando, FL on Tuesday, January 10, 2023. The presentation will begin at 3:30 p.m. ET and will include comments from Andras Bende, chief financial officer. Investors and interested parties will be able to listen to the investor presentation via webcast at https://investors.intermexonline.com/news-events/events. The archived webcast will be available shortly after the conclusion of the presentation. About International Money Express, Inc.Founded in 1994, Intermex applies proprietary technology enabling consumers to send money from the United States and Canada to 18 countries in Latin America...

Tel Aviv, Dec. 13, 2022 (GLOBE NEWSWIRE) — Citrine Global Corp. (OTCQB: CTGL) is pleased to announce the signing of a memorandum of understanding (MOU) with MyPlant Bio Ltd., a pioneering Israeli company that is specialized in botanical drug development and owns certain know-how and intellectual property rights that include a developed platform and cell-disease models to screen plant extracts to understand their biological effect, and has screening platforms using cell line models for certain diseases and conditions to detect effective plant materials and/or other substances for the treatment of these conditions. MyPlant was founded by Cannasoul Analytics, a leading botanical research and development company and Prof. Dedi Meiri from the Faculty of Biology at the Israeli Institute of Technology (Technion) and a member of the Technion...

New York, NY and Providence, RI, Dec. 13, 2022 (GLOBE NEWSWIRE) — As previously announced, on August 31, 2022, Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) entered into definitive merger agreement with Ocean Biomedical, Inc. Aesther announced today that its Board of Directors has approved an extension of the period of time available to Aesther to consummate a business combination by three months from December 16, 2022 to March 16, 2022 (the “Second Extension”), as permitted under Aesther’s governing documents. In connection with the Second Extension, Aesther’s sponsor, Aesther Healthcare Sponsor, LLC, has agreed to deposit an aggregate of $1,050,000 into Aesther’s Trust account for its public stockholders, representing $0.10 per public share, by December 16, 2022, which will be in the form of a loan. Aesther’s...

ARLINGTON, Va., Dec. 13, 2022 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (“Arqit”), a leader in quantum-safe encryption announces that it has signed with Dell Technologies (“Dell”) a “Dell OEM Engineered Solutions Pilot Agreement”. Dell agrees to preload Arqit’s QuantumCloud™ software on selected Dell hardware devices, enabling Dell sales teams to sell the combined hardware and software as a single SKU to address existing and new customer needs. The initial target market is the US Federal Government, including the Department of Defense (DoD), the Federal Civilian Agencies and the Intelligence Community. Dell sales teams will be able to offer Arqit QuantumCloud™ software and Arqit sales teams will be able to offer Dell hardware and services in their sales portfolios.  Arqit’s QuantumCloud™ is...

Expands Patient Education, Access to Non-Opioid Options for Pain Management Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the launching of a new initiative to utilize its telehealth platform to educate and provide prescription and “over the counter” non-opioid pain reduction options. The Endonovo Telehealth platform will provide alternative pain management options through its direct-to-consumer sales of prescription and non-prescription uses of their SofPulse® Pulsed Electro Magnetic Frequency (PEMF) medical device proven to reduce opioid use. Shortage of Physicians “There is a massive and acute shortage of primary care physicians and other healthcare specialists prompting the need for patient information and product distribution systems which only a telehealth platform...

Reference is made to the announcement on 23 November 2022 that Awilco Drilling PLC (“Awilco Drilling”) intended to apply for a transfer of its listing from Oslo Børs to Euronext Growth Oslo and to the announcement on 1 November 2022 that Awilco Drilling will change its structure of VPS registration to Sponsored Norwegian Depository Receipts (“SNDRs”). The first day of trading on Euronext Growth Oslo is expected to occur on 16 December 2022 and the last day of trading on Oslo Børs is expected to be on 15 December 2022. Following the listing on Euronext Growth Oslo, Awilco Drilling expects to carry out an equity offering of approx. USD 10 million, expected to be structured as combination of a private placement and a subsequent repair offering. As from the first day of trading on Euronext Growth Oslo, Awilco Drilling...

Figure 1 Grab samples collected at surface at the Jaguar Gold ZoneFigure 2 Williams Brook property main gold zonesRIMOUSKI, Quebec, Dec. 13, 2022 (GLOBE NEWSWIRE) — Puma Exploration Inc. (TSXV: PUMA, OTCQB: PUMXF) (the “Company” or “Puma”) is pleased to announce up to 34.70 g/t Au in grab samples* collected at the Jaguar Gold Zone (“JGZ”) this fall as part of the Company’s ongoing surface exploration program at its 100%-owned Williams Brook Gold Project in Northern New Brunswick. Results are consistent with widespread epithermal/orogenic gold systems, and Puma plans to extend stripping and launch an inaugural drill program at the JGZ in 2023. Figure 1: Grab samples* collected at surface at the Jaguar Gold Zone is available at the following address:https://www.globenewswire.com/NewsRoom/AttachmentNg/15d5cb3c-54f3-40d1-90a3-372d6eeec852 *The...

Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial OfficerSteven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Steven Tuch as Chief Financial Officer, effective immediately. “Steven’s success in capital raising and business development, combined with his range of work in the life science and healthcare industry, makes us confident that he is an excellent fit for the position and our needs,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. “We anticipate that he will play a pivotal role as we actively prepare to initiate, then execute on, our Phase...